Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells $867,350.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $15.77, for a total transaction of $867,350.00. Following the completion of the sale, the chief executive officer now directly owns 429,398 shares of the company’s stock, valued at approximately $6,771,606.46. This trade represents a 11.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Saurabh Saha also recently made the following trade(s):

• On Friday, December 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $17.44, for a total value of $959,200.00.
• On Friday, December 6th, Saurabh Saha sold 87,496 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.46, for a total value of $1,615,176.16.
• On Monday, November 25th, Saurabh Saha sold 299 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.23, for a total value of $5,450.77.
• On Wednesday, November 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $16.89, for a total transaction of $928,950.00.
• On Friday, November 22nd, Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.24, for a total transaction of $30,479.04.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ:CNTA opened at $16.28 on Friday. Centessa Pharmaceuticals plc has a 52 week low of $7.38 and a 52 week high of $18.97. The company has a 50-day moving average price of $16.78 and a 200 day moving average price of $14.80. The company has a market cap of $2.15 billion, a P/E ratio of -10.64 and a beta of 1.53. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.05. Research analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. First Light Asset Management LLC lifted its stake in shares of Centessa Pharmaceuticals by 59.2% in the second quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock valued at $43,168,000 after purchasing an additional 1,778,515 shares during the period. Perceptive Advisors LLC increased its holdings in Centessa Pharmaceuticals by 27.6% in the second quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company’s stock valued at $35,518,000 after buying an additional 850,000 shares in the last quarter. FMR LLC lifted its position in shares of Centessa Pharmaceuticals by 4.6% during the 3rd quarter. FMR LLC now owns 2,916,494 shares of the company’s stock valued at $46,635,000 after acquiring an additional 129,300 shares during the period. Point72 Asset Management L.P. boosted its stake in shares of Centessa Pharmaceuticals by 54.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company’s stock worth $43,423,000 after acquiring an additional 953,659 shares in the last quarter. Finally, Franklin Resources Inc. grew its holdings in shares of Centessa Pharmaceuticals by 99.1% in the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock worth $38,360,000 after acquiring an additional 1,145,823 shares during the period. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on CNTA shares. Guggenheim upped their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 15th. TD Cowen began coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating for the company. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Centessa Pharmaceuticals presently has an average rating of “Buy” and an average target price of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.